Laboratory and clinical characteristics of adjudication-confirmed VITT patients referred for VITT testing between 1 April 2021 and 7 September 2021
| Variable . | Adjudication-confirmed VITT . |
|---|---|
| n | 99 |
| Female | 55 |
| Male | 44 |
| Age, y | 63 (53-73) |
| Days’ postvaccine | 10 (8-15) |
| Platelet count at time of testing (×109/L) | 70 (37-128) |
| D-dimer (fold-change over ULN) | 40 (15-43) |
| Thrombosis | 99 |
| Cerebral venous sinus thrombosis | 28 |
| Splanchnic thrombosis | 19 |
| Pulmonary embolism | 40 |
| Deep vein thrombosis | 26 |
| Other | 21 |
| Mortality | 7 |
| Variable . | Adjudication-confirmed VITT . |
|---|---|
| n | 99 |
| Female | 55 |
| Male | 44 |
| Age, y | 63 (53-73) |
| Days’ postvaccine | 10 (8-15) |
| Platelet count at time of testing (×109/L) | 70 (37-128) |
| D-dimer (fold-change over ULN) | 40 (15-43) |
| Thrombosis | 99 |
| Cerebral venous sinus thrombosis | 28 |
| Splanchnic thrombosis | 19 |
| Pulmonary embolism | 40 |
| Deep vein thrombosis | 26 |
| Other | 21 |
| Mortality | 7 |
Continuous variables are expressed as median (interquartile range).
ULN, upper limit of normal.